The UK has the strongest and most robust clinical pipeline in Europe, with the number of drug products in development
Breaking News
- Brexit – Implications For the Pharma Industry in Ireland The UK’s referendum decision to leave the EU in May 2016 undoubtedly sent shockwaves throughout Europe. European countries are still struggling to interpret what ‘Brexit’ will mean for them. Ireland,...
- EMA to Work With Stakeholders to Improve Product Information For EU Medicines The European Medicines Agency (EMA) has published an action plan to improve the product information (PI) for EU medicines, an information package for patients and healthcare professionals that accompanies every single medicine authorised in...
- Diaceutics Wins at Export Industry Awards Diaceutics, the Irish data insights and solutions company helping patients receive potentially lifesaving medicine through better testing, won the Small & Emerging Exporter of the Year Award at the recent Export...
- Brexit – Key Issues For the Pharmaceutical Industry Brexit – the stark reality is that the UK’s EU membership and the application of all EU legislation in the UK ends automatically at midnight on 30th March 2019! Current understanding...
- European Commission Diagnoses the State of Health in the EU Only by rethinking our health systems can we ensure that they remain fit-for-purpose and provide patient-centred care. This is what the 28 Country Health Profiles recently published by the Commission,...
The European Medicines Agency (EMA) has approved Zebinix (eslicarbazepine acetate) for use as once-daily monotherapy to treat adults with newly-diagnosed
The UK government says Merck Sharp & Dohme (MSD) broke competition laws by lowering the price of its Remicade drug
Ulster University is streaming £2 million into a new health technology hub which aims to support the rapid research and
The European Medicines Agency (EMA) met with a delegation from the East African Community (EAC) from May 18–19, 2017 as
The EC granted full marketing approval for Biogen’s Fampyra® (prolonged-release fampridine) as a treatment to improve walking in people with
The Regulatory Affairs Professionals Society (RAPS) is hosting a dedicated workshop on the new EU regulations for medical devices and
World Cancer Research Fund International has released a new report that demonstrates an increased risk of breast cancer is associated
Novartis has revealed that up to 500 positions in Switzerland will be eliminated or transferred to other areas over the
GP leaders are warning that nearly 3.5 million patients are at risk of losing their family doctor, if the status
On May 22, 2017, the European Medicines Agency (EMA) announced that its Pharmacovigilance Risk Assessment Committee has completed an audit
Even before European officials present the groundwork for relocating the bloc’s drug regulator, a fight has emerged between countries vying
The State Patent Bureau of the Republic of Lithuania (SPB) and Kaunas University of Technology National Innovation and Entrepreneurship Centre
Recordati announced that it has entered into an agreement with AstraZeneca for the acquisition of the rights to Seloken®/Seloken® ZOK
Hansa Medical has accessed the EMA’s priority medicines scheme to accelerate the development of a therapy that broadens the access
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval to expand the use of
“New innovations in contraceptive technology are needed to expand the number of methods available to women and adolescents so they
Iterum Therapeutics has raised €58M to fund Phase III and bring a new antibiotic to a market where innovation is
Veltassa (patiromer), developed by Relypsa, has received a recommendation for marketing approval from the Committee for Medicinal Products for Human
Advertisements
